Content Production and Competition - The company relies on in-house teams for original content production and faces competition for qualified personnel, which may impact its content capabilities [46] - User growth for mobile and online video products has been significant, but retaining and attracting users depends on providing compelling content and quality experiences [49] - The increase in professionally-produced content in China may lead to heightened competition for users and advertising customers [54] - Maintaining and enhancing the brand is crucial for attracting users and advertisers, and any perception of low-quality content could harm brand reputation [53] - The company faces challenges in attracting and retaining highly qualified personnel, which is critical for effective growth and content production [95] Financial Risks and Capital Requirements - Significant cash is required for operations and content production, and failure to secure adequate capital could adversely affect the company's growth plans [48] - A substantial portion of revenue is generated from advertising, and the company may struggle to retain advertising customers if they find better returns elsewhere [50] - The company's revenue and net income are significantly impacted by economic conditions in China, which may be affected by trade disputes and consumer confidence [91] - The company does not foresee paying cash dividends in the foreseeable future, relying instead on capital appreciation for investor returns [98] - Payment processing risks exist, as changes in fees or regulations could adversely impact revenues and operating results [80] Market Competition and User Retention - The company operates in a highly competitive market with major competitors like Alibaba and Pinduoduo, which may affect user traffic and market share [52] - The company faces increasing competition in its industry, which could lead to a loss of market share and revenue, particularly as competitors may have larger user bases and more resources [157] - The ability to offer authentic, high-quality products on the e-commerce platform is essential for customer retention and growth [58] Technological and Regulatory Challenges - The company operates in a rapidly evolving industry, and failure to keep up with technological changes could adversely affect its business and user traffic [66] - The integration of artificial intelligence into products presents risks, including potential legal liabilities and reputational harm due to data privacy issues [69] - The company acknowledges the risks associated with the implementation of AI and machine learning technologies, which may lead to increased compliance costs and regulatory scrutiny [113] - The blockchain industry faces uncertainties regarding consumer adoption and long-term development, which could adversely affect the company's metaverse platform and other products [115] - The company operates under substantial uncertainties regarding PRC laws and regulations, which could significantly impact its business operations and financial results [166] Data Security and Compliance - The company collects and retains large volumes of customer data, necessitating strict compliance with data protection laws [186] - The company faces risks related to cybersecurity breaches, which could lead to significant legal and financial liabilities, harming its reputation and revenue [85] - The evolving PRC laws and regulations related to cybersecurity and data protection may impose significant compliance costs and operational changes on the company [201] - The Cybersecurity Review Measures may require a cybersecurity review for future overseas listings if the company is deemed a critical information infrastructure operator [189] Regulatory Environment and Foreign Investment - The company operates through Variable Interest Entities (VIEs) in China, which may face regulatory scrutiny and could impact the company's financial results if found non-compliant [120] - The PRC Foreign Investment Law, effective January 1, 2020, introduces uncertainties regarding the classification of VIE Contracts as foreign investments, which could impact the company's operations and compliance with market access requirements [135] - The company is subject to potential tax liabilities from the PRC tax authorities, which could significantly reduce its consolidated net income [127] - New regulations regarding foreign exchange and outbound investments may affect the company's ability to implement acquisition strategies [178] Market Conditions and Economic Factors - The growth of the Chinese economy has slowed down since 2012, with GDP growth at 3.0% in 2022, which may adversely affect the company's business and financial condition [163] - Future inflation in China may inhibit economic activity and adversely affect operations [174] - Fluctuations in the foreign currency exchange rate between the U.S. dollar and Renminbi could adversely affect the company's cash flows, revenues, and financial position [171] Corporate Governance and Shareholder Interests - The dual-class voting structure concentrates voting control with holders of Class B Ordinary Shares, giving them approximately 91.5% of the aggregate voting power, which may limit influence of other shareholders [231] - The company may face challenges in protecting shareholder interests due to its operations being conducted in China and management residing outside the U.S. [173] - The company's Class A Ordinary Shares may be delisted from The Nasdaq Capital Market if the bid price falls below $1.00 for thirty consecutive business days, impacting market access [233] Future Prospects and Strategic Initiatives - The company is currently developing a metaverse platform that aims to integrate intelligent retail, video on demand, social networking, and gaming experiences [109] - Significant resources are being allocated to the development and marketing of the metaverse platform, but the company cannot guarantee its success due to unpredictable factors such as consumer preferences and regulatory changes [110] - Expansion into new products and services carries inherent risks, including potential new competition and increased capital requirements [117]

Content Production and Competition - The company relies on in-house teams to generate original content and faces competition for qualified personnel, which may impact content production capabilities [46] - User growth for mobile and online video products has been significant, but retaining and attracting users depends on providing compelling content and quality experiences [49] - A substantial portion of revenue is generated from advertising, and the company may struggle to retain advertising customers if they find better returns elsewhere [50] - The increase in professionally-produced content in China may lead to heightened competition for users and advertising customers [54] - Maintaining and enhancing the brand is crucial for success, and any perception of low-quality content may adversely impact user retention [53] - The company faces fierce competition for qualified personnel, which is critical for generating high-quality video content and could impact business growth if not addressed [95] Financial Risks and Capital Requirements - Significant cash is required to fund operations and produce high-quality video content, and failure to secure adequate capital may adversely affect business prospects [48] - The company must effectively manage growth and expand infrastructure to support operations, or it may face adverse effects on financial condition [57] - The company's revenue and net income are significantly impacted by economic conditions in China, with a potential slowdown affecting consumer spending and online commerce [91] - The company does not foresee paying cash dividends in the foreseeable future, focusing instead on retaining earnings for growth [98] - Payment processing risks exist, as changes in payment ecosystems or increases in fees could adversely impact revenues and operating results [80] Regulatory and Compliance Challenges - Compliance with PRC regulations is critical, as objectionable content could lead to penalties, revocation of licenses, and reputational harm [64] - The company operates under substantial uncertainties regarding PRC laws and regulations, which could significantly impact its business operations and financial results [166] - The VIE Contracts used for operations in China may face scrutiny from regulatory authorities, which could lead to severe consequences if found non-compliant [120] - The company relies on licenses for its advertising operations, and any deterioration in the relationship with Horgos and Xing Cui Can could adversely affect business operations [138] - The advertising industry in China is subject to extensive regulation, and violations could result in penalties, including fines and revocation of business licenses, which may harm the company's reputation [149] Technology and Innovation - The company holds five invention patents in China related to its AI technologies, but challenges to these patents could impact its competitive position and revenues [70] - The integration of artificial intelligence into products presents risks, including potential legal liabilities and reputational harm due to data leakage or inaccuracies [69] - Significant investments in new product offerings and technologies, particularly in AI, are planned, but these initiatives carry inherent risks and uncertainties [75] - The company is currently developing a metaverse platform that aims to integrate intelligent retail, video on demand, social networking, and gaming experiences [109] - The blockchain industry faces uncertainties regarding consumer adoption and long-term development, which could adversely affect the metaverse platform's success [115] Cybersecurity and Data Protection - The company is vulnerable to cybersecurity breaches, which could lead to significant legal and financial liabilities, harming its reputation and revenue [85] - The company collects and retains large volumes of customer data, necessitating strict compliance with data protection laws to avoid liability for improper use [186] - The evolving PRC laws and regulations regarding cybersecurity and data protection may impose significant compliance costs and operational changes on the company [201] - Any failure to comply with cybersecurity regulations could result in significant legal and financial exposure, including fines and operational restrictions [196] Market and Economic Conditions - The growth of the Chinese economy has slowed down since 2012, with GDP growth at 3.0% in 2022, which may adversely affect the company's business and financial condition [163] - Future inflation in China may inhibit economic activity and adversely affect operations, potentially leading to government controls on credit and prices [174] - Fluctuations in the foreign currency exchange rate between the U.S. dollar and Renminbi could adversely affect the company's financial position and cash flows [171] Shareholder and Governance Issues - The company's controlling shareholder holds approximately 91.5% of the voting power, which may influence major business decisions and deter changes in control [97] - The dual-class voting structure concentrates voting control with holders of Class B Ordinary Shares, which may limit the influence of other investors on corporate matters [230] - As of December 31, 2024, Class B Ordinary Shares constitute approximately 91.5% of the aggregate voting power, allowing the chairman to control significant corporate actions [231] Operational Risks - The performance and reliability of China's Internet infrastructure are crucial for the company's operations, and disruptions could significantly affect business continuity [81] - Frequent service disruptions, whether from internal systems or third-party providers, may negatively affect user experience and harm the company's reputation [89] - The company has substantial reliance on its IT systems, and any failure could disrupt operations and adversely affect financial results [103] Future Outlook and Strategic Initiatives - The company plans to engage in the metaverse industry, leveraging blockchain technologies and artificial intelligence, but faces substantial uncertainties related to regulatory administration and governmental policies [152] - Significant resources are being allocated to the development and marketing of the metaverse platform, but the company cannot guarantee its success due to unpredictable factors such as consumer preferences and regulatory changes [110] - Expansion into new products and services carries inherent risks, including potential new competition and increased capital requirements [117]

Financial Performance - Net sales in fiscal 2025 decreased by 9.8% to $565.2 million compared to $626.6 million in fiscal 2024[160]. - Net loss in fiscal 2025 was ($16.2) million, an improvement from a net loss of ($43.6) million in fiscal 2024[160]. - Adjusted EBITDA in fiscal 2025 increased to $24.9 million, up from $14.6 million in fiscal 2024, representing 4.4% of net sales[160][178]. - Gross profit decreased by $6.9 million, or 2.2%, to $301.6 million, but gross margin improved to 53.4% from 49.2%[168]. - Selling, general and administrative expenses decreased by $27.1 million, or 8.0%, to $310.5 million, with expenses as a percentage of net sales at 54.9%[169]. - Interest expense increased to $5.2 million in fiscal 2025 from $4.6 million in fiscal 2024 due to higher outstanding debt[171]. - The decline in net sales was attributed to reduced direct-to-consumer sales and one less week in fiscal 2025[167]. Cash Flow and Capital Expenditures - Free cash flow increased by $41.8 million to $16.6 million in fiscal 2025 compared to a negative free cash flow of ($25.2) million in fiscal 2024[179]. - For fiscal 2025, net cash provided by operating activities was $24.2 million, primarily driven by a $35.2 million decrease in inventory[186]. - The company spent $17.8 million on capital expenditures in fiscal 2025, including investments in software hosting[181]. - Net cash used in investing activities for fiscal 2025 was $7.4 million, primarily for purchases of property and equipment[189]. - The company experienced a significant cash decrease of $28.8 million in fiscal 2024, compared to an increase of $13.0 million in fiscal 2025[184]. Credit and Financing - The company entered into a new credit agreement on April 28, 2025, providing for borrowings of up to $100 million[195]. - The new credit agreement allows for a maturity date of April 28, 2030, providing flexibility for seasonal inventory builds[198]. - The company has a credit facility with a revolving commitment that was amended to $100 million, down from $200 million[194]. - The company believes that cash flow from operating activities and the credit facility will be sufficient to cover working capital needs for the foreseeable future[182]. Taxation - The effective tax rate related to controlling interest was (7.8%) in fiscal 2025 compared to (5.7%) in fiscal 2024[172]. - The company uses the asset and liability method for accounting income taxes, recognizing deferred tax assets and liabilities based on differences between U.S. GAAP and tax bases[216]. - Net deferred tax assets are recorded only if they are expected to be realized, considering both positive and negative evidence[217]. - A valuation allowance was recognized for the years ended February 1, 2026, and February 2, 2025, indicating potential realizability issues with deferred income tax assets[217]. - The company establishes assets and liabilities for uncertain tax positions using a more-likely-than-not recognition threshold[218]. - Penalties and interest related to uncertain tax positions are recognized as income tax expense[218]. - The company measures deferred tax assets and liabilities using enacted tax rates expected to be in effect when differences reverse[216]. - The company considers future taxable income and tax planning strategies in determining the realizability of deferred tax assets[217]. - Further details on income taxes can be found in Note 9 of the Consolidated Financial Statements included in the Annual Report[219]. Operational Developments - The company opened two new stores, contributing to an increase in store net sales[167]. - As of February 1, 2026, the company's working capital was $63.8 million, including cash and cash equivalents of $16.3 million[180]. - For fiscal 2024, net cash used in operating activities was $16.9 million, with a net loss of ($43.6) million[188]. - The company has not made any material changes to its assumptions regarding obsolescence and shrinkage reserves during the reported periods[215]. - The company has not recorded significant adjustments related to the physical inventory process during the periods presented[215].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-41153 ALPHA STAR ACQUISITION CORPORATION (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or oth ...

Financial Performance - The company reported a net loss of $(847,048) for the year ended December 31, 2025, compared to a net income of $1,344,563 for 2024, with formation and operational costs of $887,584 and $913,909 respectively[197]. - Net cash used in operating activities was $(651,811) for 2025, compared to $(243,395) for 2024, primarily due to the net loss and changes in interest earned[200]. Initial Public Offering - The company generated gross proceeds of $115,000,000 from the initial public offering of 11,500,000 Units and an additional $3,300,000 from the sale of 330,000 Private Units[198]. - The company incurred $5,669,696 in transaction costs related to the initial public offering, including $2,300,000 in underwriting fees[199]. - The deferred underwriting commissions were reduced from $2,875,000 to $950,000, to be paid upon the closing of a business combination[214]. Trust Account and Investments - As of December 31, 2025, the company had investments held in the Trust Account amounting to $718,072, down from $11,111,853 in 2024[201]. - The company has no cash held outside the Trust Account as of December 31, 2025, and intends to use funds from the Trust Account to complete its business combination[202]. - The net proceeds from the initial public offering and private placement units will be invested in U.S. government treasury bills with a maturity of 185 days or less[222]. - The investments will also include money market funds that comply with Rule 2a-7 under the Investment Company Act, focusing on direct U.S. government treasury obligations[222]. - Due to the short-term nature of these investments, the company anticipates no material exposure to interest rate risk[222]. Capital and Financing - The company issued promissory notes totaling $6,245,961 to the Sponsor, which are repayable upon the consummation of the initial business combination[208]. - The company plans to raise additional capital to meet expenditures required for operating its business and completing a business combination[210]. - The company has no off-balance sheet financing arrangements or long-term liabilities other than a monthly fee of $10,000 to the Sponsor for administrative services[211][212].

Financial Performance - Consolidated net income for 2025 was $11.1 million, an increase of 26.1% from $8.8 million in 2024, with basic earnings per share rising to $2.43 from $1.94[193]. - Total consolidated assets increased by 5.8% to $1.62 billion in 2025, up from $1.53 billion in 2024[195]. - Total investments rose by 30.1% to $328.3 million, representing 20.3% of total assets, compared to 16.5% in 2024[195]. - Net loans and loans held for sale increased by 1.5% to $1.17 billion, accounting for 72.5% of total assets[195]. - Total deposits grew by 3.9% to $1.21 billion in 2025, compared to $1.17 billion in 2024[196]. - The Company's total capital increased to $80.9 million in 2025 from $66.5 million in 2024, reflecting net income and a decrease in accumulated other comprehensive loss[197]. - Return on average assets improved to 0.71% in 2025 from 0.60% in 2024, while return on average equity rose to 15.29% from 13.38%[199]. - Net interest income increased by $4.8 million to $44.0 million for 2025, compared to $39.3 million in 2024[211]. - The net interest margin improved to 2.93% in 2025 from 2.77% in 2024, driven by a 24 basis points increase in average yield on interest earning assets[210]. - The tax equivalent net interest income for 2025 was $44,034 thousand, compared to $39,270 thousand in 2024[217]. Regulatory Environment - The Dodd-Frank Act has increased regulatory requirements, including provisions for executive compensation and capital standards[36]. - The Company is subject to regulation and supervision by the FRB, FDIC, and DFR, which impacts its operational flexibility[32]. - The Company has not elected to become a financial holding company, limiting its activities to banking and related services[41]. - Union is subject to the Community Reinvestment Act, which mandates banks to serve the credit needs of low- and moderate-income communities[48]. - The company is required to comply with enhanced customer due diligence regulations since 2018, focusing on the collection of information on beneficial owners of legal entity customers[70]. - The company and Union are required to comply with various consumer protection laws, including the Dodd-Frank Act, which imposes additional disclosure requirements[63]. - The Company has adopted a clawback policy in November 2023, aligning with new regulatory requirements for executive compensation[45]. - The capital adequacy guidelines require a minimum common equity Tier 1 capital ratio of 4.5% and a minimum Tier 1 risk-based ratio of 6.0%[51]. - The FDICIA restricts brokered deposits unless the institution is well capitalized; Union has established accounts with approved investment brokers to accept such deposits[47]. - As of the latest examination, Union has no enforcement actions against it, indicating a stable regulatory standing[44]. Operational Risks - The Company faces risks related to environmental liabilities from properties acquired through foreclosure, which could lead to significant costs[98]. - The performance of the Federal Home Loan Bank of Boston is critical for the Company's liquidity needs, and any deterioration could adversely affect financial condition[96]. - The Company may incur fines and penalties from regulatory violations, which could have a material adverse effect on its business and reputation[107]. - The company faces risks from operational fraud, including check fraud and wire fraud, which could adversely affect financial results[126]. - The company relies on third-party vendors for critical infrastructure, which poses risks of operational failures and potential financial losses[127]. - Cybersecurity threats and attacks are a significant risk, potentially leading to unauthorized access and financial losses[128]. - The company maintains an insurance policy for cybersecurity risks, but there is no assurance it will cover all potential losses[132]. - The accuracy of financial statements may be affected by judgments and estimates in critical accounting policies[114]. - The company's Board of Directors oversees the risk management framework, including cybersecurity, to ensure compliance with applicable regulations[152]. - Regular cybersecurity risk assessments and monitoring are conducted to identify vulnerabilities and enhance the company's resilience against cyber threats[157]. Market Conditions - Competition for loans and deposits is strong, with the Company focusing on personal service and community relationships to attract customers[25]. - The Company seeks to capitalize on local autonomy and personal service to compete with larger financial institutions[26]. - The financial services industry is highly competitive, with emerging technologies intensifying competition and potentially disrupting traditional banking services[149]. - Competition in the local banking industry may impair the company's ability to attract and retain customers, impacting loan growth and financial condition[138]. - The company faces significant risks from external economic factors, including changes in monetary policy and inflation, which could adversely affect financial performance[144]. - General market and economic conditions, including interest rates and unemployment, continue to impact the company's financial results and may lead to increased loan delinquencies[145]. Employee and Workplace - The Company employed 195 full-time employees as of December 31, 2025, emphasizing a supportive workplace and competitive compensation[22]. - The Company has a whistleblower program to ensure a safe workplace and promote reporting of safety concerns[22]. Loan and Deposit Management - For the year ended December 31, 2025, the Company's rate of average loans to average deposits was 98.4%[24]. - The Company offers a variety of services, including commercial loans, residential mortgages, and online banking services[23]. - As of December 31, 2025, approximately 41% of the company's loan portfolio consisted of commercial and commercial real estate loans, which historically pose greater credit risks compared to residential mortgage loans[85]. - The carrying value of the company's investment securities portfolio was approximately $326.3 million as of December 31, 2025, with potential fluctuations in fair value due to external factors[89]. - The company has adopted asset and liability management policies to minimize the adverse effects of interest rate changes on net interest income, which is crucial for profitability[86]. - The company maintains an allowance for credit losses to cover expected loan defaults, which may need to be increased based on regulatory evaluations and market conditions[82]. - Prepayments of loans by customers may negatively affect the Company's interest income, impacting overall financial performance[97]. - Interest expense increased primarily due to higher utilization of wholesale funding and increased rates on customer deposits[191]. - The Company continues to manage net interest margin and spread through disciplined loan and deposit pricing strategies[192]. Growth and Expansion - The company has expanded its banking operations into New Hampshire, including the opening of new branches in Lincoln (2014) and North Conway (2023)[68]. - The Company operates 13 community banking locations in Vermont and five in New Hampshire as of December 31, 2025[161].

Revenue Performance - Net revenue increased by 33% to $0.8 million in Q4 2025, compared to $0.6 million in Q4 2024[4] - FY 2025 net revenue decreased to $2.6 million from $3.2 million in FY 2024[4] - Net revenue for the year ended December 31, 2025, was $2,553 million, a decrease of 20% from $3,189 million in 2024[27] Gross Margin - Gross margin improved to 57.7% in Q4 2025, up from 23.3% in Q4 2024, representing a 3,443 basis point increase[4] - FY 2025 gross margin increased by 500 basis points to 50.6%, compared to 45.6% in FY 2024[4] Cash and Cash Equivalents - Cash and cash equivalents totaled $100.6 million as of December 31, 2025[4] - Cash and cash equivalents at the end of the period were $100,587 million, down from $112,974 million at the beginning of the period[29] Operating Expenses and Losses - Total operating expenses increased significantly to $21,810 million in 2025, up 42.3% from $15,343 million in 2024[27] - Operating loss widened to $20,519 million in 2025, compared to a loss of $13,889 million in 2024[27] - Net loss for 2025 was $11,401 million, an increase from a net loss of $10,316 million in 2024[27] - Net loss per share improved to $(0.57) in 2025 from $(0.94) in 2024[27] Investment and Product Development - The company introduced two hospitality-specific product tiers aimed at enhancing guest experiences and driving revenue growth[3] - Continued investment in artificial intelligence, with a focus on guest personalization, is expected to capitalize on a projected 50% allocation of AI budgets in hospitality by 2030[7] - The AI Concierge product, which integrates real-time conversational AI with navigation technology, is now commercially available following a successful pilot program[9] - The company plans to expand its sales and marketing initiatives to drive adoption of its AI Concierge and future AI-enabled capabilities[12] Liabilities - Phunware's total liabilities increased to $24.6 million in 2025 from $7.6 million in 2024[25] Other Income - Total other income increased to $9,099 million in 2025, compared to $3,614 million in 2024[27] Cash Flow from Operations - Net cash used in operating activities from continued operations was $12,467 million in 2025, slightly improved from $13,125 million in 2024[29] - Proceeds from sales of common stock were $80 million in 2025, significantly lower than $122,342 million in 2024[29]

Financial Performance and Losses - The company incurred net losses of €45.6 million, €46.1 million, and €42.7 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of €377.8 million as of December 31, 2025[54]. - The company expects to continue incurring significant net losses as it advances izicopan into additional clinical trials, with cash used for operating activities amounting to €35.3 million and €48.6 million for the years ended December 31, 2025, and 2024, respectively[55][61]. - The company anticipates needing substantial additional funding to continue its operations and may face delays or reductions in product development if unable to raise capital[61][64]. - The company may incur significant commercialization expenses related to product sales, marketing, and distribution if it obtains marketing approval for its product candidates[61]. - The company may face significant fluctuations in financial condition and operating results from quarter to quarter and year to year due to various uncontrollable factors[69]. Regulatory Approvals and Market Authorization - The company received Emergency Use Authorization (EUA) for GOHIBIC (vilobelimab) in the United States in April 2023 and market authorization in Europe in January 2025[66]. - The company has not yet received marketing approval for any product candidates, which poses a risk to future revenue generation[99]. - The marketing approval process is lengthy and uncertain, with no current applications submitted for any product candidates in the U.S. or other jurisdictions[98]. - The company is not permitted to market any product candidates without obtaining necessary marketing approvals from regulatory authorities[76]. - The company received Emergency Use Authorization (EUA) for GOHIBIC (vilobelimab) in April 2023, but it remains subject to ongoing regulatory oversight[78]. Clinical Trials and Development Risks - The clinical development of product candidates is subject to significant risks, including potential failure at any stage, which may delay regulatory approval for years[88]. - Inability to complete clinical trials could lead to additional costs and impair revenue generation from product sales and milestones[89]. - Failure to demonstrate safety and efficacy in clinical trials would significantly harm the company's business prospects[90]. - Patient enrollment in clinical trials is critical, and difficulties in this area could delay development and revenue generation[104]. - The company acknowledges that delays in clinical trials could significantly increase product development costs and impair commercialization efforts[125]. Intellectual Property and Patent Risks - The success of the company depends on obtaining and maintaining intellectual property protection for its product candidates, which is a complex and costly process[178]. - The patent position of the company may be uncertain, and challenges to patents could limit the ability to prevent competitors from commercializing similar products[180]. - The company’s patent portfolio consists of six families of patents related to C5a and C5aR inhibitors, but the breadth of claims that may be allowed or enforced is unpredictable[192]. - The company cannot assure that any of its patent applications will be found patentable, which could limit its competitive advantage[193]. - The company may struggle to enforce its intellectual property rights globally due to varying patent laws and enforcement challenges in different jurisdictions[212]. Manufacturing and Supply Chain Risks - The company relies on third-party manufacturers for the clinical and commercial supply of vilobelimab, which introduces risks related to political and economic disruptions, particularly in China[159]. - Manufacturing biologics like vilobelimab is highly susceptible to product loss due to contamination, equipment failure, and other risks, which could lead to significant delays in development programs[164]. - The manufacturing process is subject to quality control risks, and any failure to comply with cGMP standards could adversely affect the company's operations and financial results[165]. - The inability of third-party manufacturers to scale production or optimize yield may increase manufacturing costs and delay commercialization[169]. - The company may incur additional costs and delays if it needs to secure alternative supply arrangements for its products[160]. Competition and Market Challenges - Market acceptance by physicians and patients is crucial for commercial success, and existing therapies may hinder the adoption of new products[107]. - The company faces challenges in obtaining adequate reimbursement levels from third-party payors, which could affect pricing and demand for its products[112]. - The company may face significant uncertainty related to third-party payor coverage and reimbursement for newly approved drugs, which could impact revenue generation[114]. - The company is focusing on developing product candidates for specific indications deemed most likely to succeed, potentially foregoing other profitable opportunities[120]. - Competition for collaboration agreements is significant, and the success of these collaborations will depend on various factors including the differentiation of product candidates and regulatory approval likelihood[171]. Employee and Operational Risks - As of December 31, 2025, the company had 65 full-time or part-time employees, indicating limited resources for operations and development[225]. - The biotechnology and pharmaceuticals industry has experienced high turnover rates, which could hinder the company's ability to implement its business strategy successfully[227]. - The company faces intense competition for hiring qualified personnel, which may limit its ability to attract and retain key employees[228]. - Misconduct by employees, contractors, or consultants could lead to significant liability and harm the company's reputation[231]. - The company relies heavily on its executive officers and directors, and their loss could materially harm business operations[226]. Financial Market and Shareholder Risks - The trading price of the company's ordinary shares has been highly volatile, influenced by various factors including clinical trial results and regulatory actions[232]. - Future sales of a substantial number of ordinary shares could adversely affect the share price and dilute existing shareholders[234]. - The company has an at-the-market program for the sale of ordinary shares with an aggregate offering price of up to $75 million, which may impact share price[234]. - The company has registered ordinary shares under its equity incentive plans, allowing for potential dilution if these shares are sold in the public market[235]. - The company must maintain and renew its operational structure to avoid disruptions, which requires significant capital expenditure[230].

Financial Performance - Milestone Pharmaceuticals reported a net loss of $63.1 million or $0.75 per share for the full year 2025, compared to a net loss of $41.5 million or $0.67 per share for the prior year[15]. - Milestone Pharmaceuticals reported revenue of $1,546,000 for the year ended December 31, 2025, compared to $0 in 2024[37]. - The net loss for 2025 was $63,058,000, compared to a net loss of $41,519,000 in 2024, indicating an increase in losses of about 52%[37]. - Total liabilities increased to $71,792,000 in 2025 from $62,352,000 in 2024, which is an increase of approximately 15%[35]. - Shareholders' equity improved to $41,769,000 in 2025, up from $13,147,000 in 2024, representing a growth of about 217%[35]. Revenue and Cash Position - The company recorded $1.5 million in revenue for the fourth quarter of 2025, resulting from a milestone payment related to the FDA approval of CARDAMYST[15]. - As of December 31, 2025, Milestone had cash, cash equivalents, and short-term investments of $106.0 million, up from $69.7 million at the end of 2024[15]. - Cash and cash equivalents rose significantly to $73,046,000 in 2025, up from $25,314,000 in 2024, marking an increase of about 188%[35]. - Milestone anticipates a cash runway supported by a $94 million financing from the RTW Royalty Purchase Agreement[32]. Product Development and Approvals - CARDAMYST nasal spray was approved by the FDA on December 12, 2025, marking the first new treatment option for over two million patients with PSVT in 30 years[5][6]. - Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared to placebo[5]. - The marketing authorization application for etripamil nasal spray in PSVT has been accepted by the European Medicines Agency, with a decision expected by the first half of 2027[10]. - Milestone plans to initiate a Phase 3 program for etripamil in patients with AFib-RVR, leveraging the initial PSVT indication[8]. - The company plans to commence a Phase 3 study in AFib-RVR, with expectations for future interactions with regulatory bodies like the FDA and EMA[30]. Sales and Marketing - The national sales force was fully deployed within eight weeks of FDA approval, consisting of approximately 60 sales representatives targeting cardiologists and electrophysiologists[10]. - Commercial expenses for the fourth quarter of 2025 were $8.2 million, compared to $4.4 million for the prior year period, driven by increased personnel and operational costs for the launch of CARDAMYST[15]. Research and Development - Research and development expenses net of tax credits were $18,108,000 in 2025, compared to $14,357,000 in 2024, reflecting a rise of approximately 26%[37]. - Total current assets increased to $111,921,000 in 2025 from $73,926,000 in 2024, representing a growth of approximately 51%[35]. - The weighted average number of shares outstanding increased to 83,882,800 in 2025 from 62,210,702 in 2024, indicating a rise of approximately 35%[37].

Employment and Workforce - As of January 31, 2026, the company employed approximately 33,000 associates, with about 21,000 being part-time[69]. - The company emphasizes a high-performance culture where associates are empowered and engaged to deliver their best work[64]. - The company has a strong focus on community impact, supporting associates in giving back through donation matching and volunteer opportunities[67]. Financial Position - The company's outstanding long-term debt as of January 31, 2026, includes $383 million in variable interest rate borrowings under the Term Loan Facility[312]. - The principal value of the company's outstanding debt as of January 31, 2026, is $983 million, with an estimated fair value of $971 million[313]. - The investment portfolio as of January 31, 2026, primarily consists of money market funds and bank deposits, with no material risk to principal from interest rate changes[311]. Risk Management - The company has operations in foreign countries, exposing it to foreign currency exchange rate fluctuations, particularly in Canadian dollars, Chinese Yuan, and Euros[309]. - The company utilizes derivative financial instruments to manage exposure to market risks, including foreign currency and interest rate risks[308]. Compensation and Equity - The company is committed to pay equity across gender, race, and background, conducting periodic third-party reviews to ensure fairness in pay programs[71]. - The company’s competitive compensation and benefits include paid parental leave, tuition assistance, and wellness programs[70].